CRISPR Therapeutics AG (CRSP)
CRSP Stock Price Chart
Explore CRISPR Therapeutics AG interactive price chart. Choose custom timeframes to analyze CRSP price movements and trends.
CRSP Company Profile
Discover essential business fundamentals and corporate details for CRISPR Therapeutics AG (CRSP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Oct 2016
Employees
393.00
Website
https://www.crisprtx.comCEO
Samarth Kulkarni
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
CRSP Financial Timeline
Browse a chronological timeline of CRISPR Therapeutics AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$1.31, while revenue estimate is $9.17M.
Earnings released on 4 Aug 2025
EPS came in at -$1.29 surpassing the estimated -$1.47 by +12.24%, while revenue for the quarter reached $892.00K , missing expectations by -90.55%.
Earnings released on 6 May 2025
EPS came in at -$1.58 falling short of the estimated -$1.27 by -24.41%, while revenue for the quarter reached $865.00K , missing expectations by -85.50%.
Earnings released on 11 Feb 2025
EPS came in at -$0.44 surpassing the estimated -$1.15 by +61.74%, while revenue for the quarter reached $35.00M , beating expectations by +334.51%.
Earnings released on 5 Nov 2024
EPS came in at -$1.01 surpassing the estimated -$1.33 by +24.06%, while revenue for the quarter reached $602.00K , missing expectations by -92.18%.
Earnings released on 5 Aug 2024
EPS came in at -$1.49 falling short of the estimated -$1.37 by -8.76%, while revenue for the quarter reached $517.00K , missing expectations by -96.88%.
Earnings released on 8 May 2024
EPS came in at -$1.43 surpassing the estimated -$1.63 by +12.27%, while revenue for the quarter reached $504.00K , missing expectations by -85.76%.
Earnings released on 21 Feb 2024
EPS came in at $1.10 surpassing the estimated -$0.07 by +1.67K%, while revenue for the quarter reached $200.00M , beating expectations by +611.49%.
Earnings released on 6 Nov 2023
EPS came in at -$1.41 surpassing the estimated -$1.98 by +28.79%.
Earnings released on 7 Aug 2023
EPS came in at -$0.98 surpassing the estimated -$2.18 by +55.05%, while revenue for the quarter reached $70.00M , beating expectations by +3.99K%.
Earnings released on 8 May 2023
EPS came in at -$0.67 surpassing the estimated -$1.67 by +59.88%, while revenue for the quarter reached $100.00M , beating expectations by +5.75K%.
Earnings released on 21 Feb 2023
EPS came in at -$1.41 surpassing the estimated -$2.32 by +39.22%, while revenue for the quarter reached $6.00K , missing expectations by -73.89%.
Earnings released on 1 Nov 2022
EPS came in at -$2.24 surpassing the estimated -$2.30 by +2.61%, while revenue for the quarter reached $94.00K , missing expectations by -94.91%.
Earnings released on 8 Aug 2022
EPS came in at -$2.40 falling short of the estimated -$2.23 by -7.62%, while revenue for the quarter reached $158.00K , missing expectations by -92.86%.
Earnings released on 9 May 2022
EPS came in at -$2.32 falling short of the estimated -$1.91 by -21.47%, while revenue for the quarter reached $178.00K , missing expectations by -93.64%.
Earnings released on 15 Feb 2022
EPS came in at -$1.84 falling short of the estimated -$1.74 by -5.75%, while revenue for the quarter reached $12.35M , beating expectations by +465.05%.
Earnings released on 3 Nov 2021
EPS came in at -$1.67 surpassing the estimated -$1.69 by +1.18%, while revenue for the quarter reached $329.00K , missing expectations by -60.54%.
Earnings released on 29 Jul 2021
EPS came in at $9.44 surpassing the estimated $3.52 by +168.18%, while revenue for the quarter reached $900.20M , beating expectations by +6.41%.
Earnings released on 27 Apr 2021
EPS came in at -$1.51 falling short of the estimated -$1.45 by -4.14%, while revenue for the quarter reached $202.00K , missing expectations by -83.31%.
Earnings released on 16 Feb 2021
EPS came in at -$1.50 falling short of the estimated -$1.23 by -21.95%, while revenue for the quarter reached $194.00K , missing expectations by -92.24%.
Earnings released on 28 Oct 2020
EPS came in at -$1.32 falling short of the estimated -$1.17 by -12.82%, while revenue for the quarter reached $148.00K , beating expectations by +11.86%.
CRSP Stock Performance
Access detailed CRSP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.